Ghetti G, Porta C, Povero M. Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy. Farmeconomia. Health Economics and Therapeutic Pathways. 2025;26(1). https://doi.org/10.7175/fe.v26i1.1574